CHI hosts the Next Generation Dx Summit where they convene more than 1,000 international diagnostic professionals for valuable networking and comprehensive programming spanning from clinical diagnostics to business strategy. The event has grown to include novel immunotherapy biomarkers, cell-free DNA, companion diagnostics, infectious disease, point-of-care, pharmacy-based diagnostics, clinical NGS assays, commercialization, reimbursement, prenatal testing, circulating tumor cells, critical care, forensics, digital PCR, microfluidics, and microbiome diagnostics. The Next Generation Dx Summit is a must-attend event with complete coverage of the most timely and important issues for the industry.
XIFIN was proud to participate as a Premier Sponsor and speaker.
Join Kyle Fetter, VP & General Manager of Diagnostic Services, XIFIN, Inc., for the session "Novel Diagnostic Technologies: Coverage Today and in the Future." Kyle will discuss how early stage and wearable diagnostic device companies face great hurdles to commercialization and reimbursement. The combination of clinical research, market adoption, and reimbursement challenges makes it imperative to synch up efforts. Understand the necessary tools with information on current challenges and how diagnostics companies are positioning themselves for success.
Novel Diagnostic Technologies: Coverage Today and in the Future
Kyle Fetter, VP & General Manager of Diagnostic Services, XIFIN, Inc.
Evidence-Based Coverage and Reimbursement Session
Tuesday, August 15, 2017
12:30 PM – 1:00 PM
Cambridge Healthtech Institute (CHI) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations.